NSCLC
Merck KGaA pipeline hit
December 21, 2012Research and Development, Sales and Marketing Cancer, Merck KGaA, NSCLC, pipeline
Merck KGaA’s pipeline has been dented by the ‘disappointing’ late-stage failure of Stimuvax in a programme with non-small cell lung …
Boehringer submits new lung cancer drug
September 20, 2012Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib
Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …
NICE final yes for Zytiga and Tarceva
June 27, 2012Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga
In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …
Discount sways NICE into recommending Tarceva
May 10, 2012Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer
NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease. The watchdog said …
DSM sees green shoots for pharma unit in Q1
May 8, 2012Business Services, Manufacturing and Production, Sales and Marketing DSM, Kensey Nash, NSCLC, Q1, Sinochem
DSM said its pharmaceutical business unit posted ‘weak’ financials in the first quarter of 2012, although revenues rose and there …
Merck does cancer drug deal with Endocyte
April 17, 2012Research and Development, Sales and Marketing Cancer, Endocyte, Merck, NSCLC, vintafolide
Merck is to pay $120 million to US biopharma company Endocyte as part of a deal to develop and commercialise …
Tarceva approval for first-line use in EGFR lung cancer
September 1, 2011Sales and Marketing NSCLC, Roche, Tarceva
Tarceva has been granted final European approval for patients with a genetically distinct type of non-small cell lung cancer (NSCLC). …
Tarceva impresses again as it seeks to extend its EU licence
June 3, 2011NSCLC, Roche, Tarceva
Roche and its partner OSI Pharmaceuticals have released another series of positive results for its lung cancer drug Tarceva as …
Pfizer files lung cancer drug in US and Japan
May 18, 2011Sales and Marketing NSCLC, Pfizer, crizotinib
Pfizer has submitted its oral lung cancer drug crizotinib for regulatory approval in the US and Japan. Crizotinib is an …
Amgen’s novel lung cancer drug disappoints in phase III
April 1, 2011Research and Development Amgen, Millennium, NSCLC, Takeda, motesanib, non-small cell lung cancer
Amgen’s lung cancer drug motesanib has not meet its primary endpoint in a phase III study. The drug, developed in …
Merck re-submits Erbitux to the EMA for lung cancer
March 30, 2011Sales and Marketing EGFR, Erbitux, Iressa, Merck KGaA, NSCLC, Tarceva, lung cancer drugs, non-small cell lung cancer
Merck KGaA has re-submitted Erbitux’s lung cancer licence extension to the EMA after its first application to the regulator was …
Sanofi lung cancer drug fails in late-stage trial
March 11, 2011Research and Development Cancer, NSCLC, Regeneron, Sanofi-Aventis, aflibercept, non-small cell lung cancer
Sanofi-Aventis’ lung cancer drug aflibercept has failed to meet its primary endpoint in a phase III trial. The late-stage VITAL …
No magic bullet, but a growing arsenal against lung cancer
February 23, 2011Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer
A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …
Blood clot fears halt cancer trial enrolment
February 3, 2011Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer
Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …
Tarceva set for first line treatment
January 31, 2011Sales and Marketing Iressa, NSCLC, Roche, Tarceva
Roche’s lung cancer treatment Tarceva has been shown to help patients as a first line treatment. An independent data monitoring …
Latest content
Five Facts about cardiovascular disease
